The treatment of cholesterol could use some clarification. As the author notes, statins reduce MI risk and they reduce cholesterol (LDL cholesterol specificall

The treatment of cholesterol could use some clarification. As the author notes, statins reduce MI risk and they reduce cholesterol (LDL cholesterol specifically). He then addresses torcetrapib, which was designed to raise HDL-cholesterol. This was testing quite a different hypothesis from that of statins. I don't think it makes sense to lump these two together and say "sometimes cholesterol works and sometimes it doesn't". Rather, it's more fruitful to see the biomarkers separately.